Moderna skyrockets 11% after receiving additional $472 million of funding, starting Phase 3 trial of COVID-19 vaccine – Business Insider Australia

• Moderna on Sunday announced it received a commitment of up to $US472 million in additional funding from its contract with the Biomedical Advanced Research and Development Authority.
• The company on Monday announced that the Phase 3 trial for its COVID-19 vaccine had started dosing participants.
• Shares of Moderna surged as much as 11% in premarket trading Monday
• Watch Moderna trade live on Markets Insider.
• Read more on Business Insider.

Shares of …

Click here to view the original article.